Workflow
Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off

Group 1 - Tarsus Pharmaceuticals has successfully launched Xdemvy (lotilaner) for Demodex blepharitis, achieving sales exceeding $100 million per quarter [1] - The company's selling, general, and administrative expenses (SG&A) have also increased alongside sales [1] - The company is following a "Get Big Fast" strategy, which was previously rated as a buy [1]